The SMN2 transgenic mouse, Tg(SMN2)89Ahmb, has emerged as the most widely used in spinal muscular atrophy (SMA) research. Here we clone the genomic integration site of the transgene and demonstrate it to be in intron 4 of the metabotropic glutamate receptor 7 (mGluR7) gene. We found that the integration of this transgene significantly reduced both mGluR7 mRNA and protein levels (24% and 9%, respectively). To determine if phenotypes associated with mGluR7 knockout mice were present in Tg(SMN2)89Ahmb containing mice, we subjected mice homozygous for the transgene to open field and seizure susceptibility tests. When compared to wild type FVB/N mice, Tg(SMN2)89Ahmb tg/tg mice exhibited significantly longer times in finding a safe wall-adjacent square (+ 54 s if Smn +/+ , + 90 s if Smn +/− ), as well as a significantly higher frequency of generalized seizure in response to a subthreshold dose of pentylenetrazol (0.11 vs 0.45). These findings aid in explaining the sudden unexpected death that occurs within SMA mouse colonies that contain a homozygous Tg(SMN2)89Ahmb transgene. This should be taken into account in pre-clinical studies that utilize this transgene, especially in therapy-treated SMA mice that have extended survival.
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Introduction
Proximal spinal muscular atrophy (SMA) is a neurodegenerative disorder that affects 1 in every 10,000 live births. It is the leading hereditary cause of infant mortality and has a carrier frequency of 1 in 40 (Crawford and Pardo, 1996; Melki et al., 1990) . SMA is characterized by progressive loss of lower motor neurons. This generates a functional interruption of the neuromuscular junction and directly results in muscle atrophy. As disease advances, terminal endpoints are often associated with pulmonary complications, although patients can survive for many years in an intubated state (Zerres and Rudnik-Schoneborn, 1995) .
Genetically, SMA is caused by loss of function mutations in the survival motor neuron (SMN1) gene (Lefebvre et al., 1995) . SMN plays a housekeeping function in RNA processing, and for this reason the complete absence of SMN protein is lethal to all cell types (Pellizzoni et al., 1998; Schrank et al., 1997) . However, during a recent point in evolution the SMN gene was duplicated, generating two distinct copies, SMN1 and SMN2. The two genes are nearly identical except for a critical C to T nucleotide transition that causes SMN2's exon 7 to be excluded from~90% of its transcripts, referred to hereafter as Δ7SMN. Importantly, the~10% of full length transcripts that contain exon 7 (FL-SMN) are enough to compensate for the loss of SMN1 in all cell types except motor neurons, causing the SMA phenotype.
Since mice lack a duplicated Smn genomic region, they cannot naturally replicate the disease. To confirm SMN2's modifying ability and model SMA in mice, two separate SMN2 transgenic models were developed and distributed to the research community (Hsieh-Li et al., 2000; Monani et al., 2000) . Despite having comparable SMN2 copies, the mouse developed by the Burghes Laboratory (Tg(SMN2)89Ahmb ) survived until 14 days of age (Gogliotti et al., 2010; Hsieh-Li et al., 2000) . The Burghes Laboratory mouse reaches the survival equivalency of the Li mouse when a high-copy Δ7SMN cDNA transgene is combined with it (commonly referred to as the "delta 7" mouse, JAX #005025) (Le et al., 2005) . Tg(SMN2)89Ahmb containing mice are the most commonly used in SMA research, and to date are the standard models for pre-clinical drug studies. Neurobiology of Disease 43 (2011) 142-151 
